China Biologic raises equity share to 76%

September 9, 2014 | Tuesday | News | By BioSpectrum Bureau

China Biologic is a plasma-based biopharmaceutical company

China Biologic is a plasma-based biopharmaceutical company

Singapore: China Biologic Products has acquired an additional 19.84 percent equity interest in Guizhou Taibang Biological Products, raising shares from 56.39 percent to 76.23 percent.

China Biologic is a plasma-based biopharmaceutical company in China. The company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases.

Sign up for the editor pick and get articles like this delivered right to your inbox.

+Country Code-Phone Number(xxx-xxxxxxx)

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

Survey Box

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls